Kuo Hann-Chorng
Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan.
Urology. 2008 Nov;72(5):1056-60. doi: 10.1016/j.urology.2008.04.026. Epub 2008 Jun 4.
To investigate satisfaction in terms of quality-of-life (QOL) improvement among patients with spinal cord lesions and detrusor sphincter dyssynergia treated with botulinum toxin A (BoNT-A) injections to the detrusor for urinary incontinence and bladder dysfunction.
A total of 50 patients with spinal cord lesion and detrusor sphincter dyssynergia were treated with BoNT-A injections (200 U) into the urinary bladder detrusor muscle. The urodynamic parameters, QOL scores, and general satisfaction with the treatment were assessed.
Overall satisfactory results were perceived by 78% of patients who received detrusor BoNT-A injections. The maximal bladder capacity had increased significantly (221 +/- 107 vs 432 +/- 115 mL, P = .000), detrusor pressure decreased (43.5 +/- 21.1 vs 12.6 +/- 10.7 cm H(2)O, P = .000), and postvoid residual urine volume increased (121 +/- 107 vs 325 +/- 123 mL, P = .000) by 3 months after BoNT-A treatment. Patients had significant improvement in QOL indexes (Urogenital Distress Inventory 6-item short form 11.7 +/- 2.3 vs 4.1 +/- 2.1, P = .01; and Incontinence Impact Questionnaire, 7-item short form 16.3 +/- 3.5 vs 11.7 +/- 4.1, P = .03) after BoNT-A treatment. Decreases in incontinence grade and urgency episodes contributed the most to satisfaction, and increased difficulty in urination and the need for catheterization contributed to dissatisfaction. Of the 50 patients, 25 (50%) received repeated BoNT-A injections; 4 patients finally decided to undergo augmentation enterocystoplasty because they desired permanent corrections and did not wish to receive repeated injections.
The patient satisfaction rate was 78%, and QOL improved among these patients after detrusor BoNT-A injections for urinary incontinence and bladder dysfunction.
研究脊髓损伤合并逼尿肌括约肌协同失调患者,接受肉毒杆菌毒素A(BoNT-A)注射至逼尿肌以治疗尿失禁和膀胱功能障碍后,在生活质量(QOL)改善方面的满意度。
共50例脊髓损伤合并逼尿肌括约肌协同失调患者接受了BoNT-A(200单位)注射至膀胱逼尿肌。评估尿动力学参数、QOL评分及对治疗的总体满意度。
接受逼尿肌BoNT-A注射的患者中,78%认为总体结果令人满意。BoNT-A治疗3个月后,最大膀胱容量显著增加(221±107 vs 432±115 mL,P = .000),逼尿肌压力降低(43.5±21.1 vs 12.6±10.7 cm H₂O,P = .000),排尿后残余尿量增加(121±107 vs 325±123 mL,P = .000)。BoNT-A治疗后,患者的QOL指标有显著改善(泌尿生殖系统困扰量表6项简表11.7±2.3 vs 4.1±2.1,P = .01;尿失禁影响问卷7项简表16.3±3.5 vs 11.7±4.1,P = .03)。尿失禁等级和急迫性发作次数的减少对满意度贡献最大,而排尿困难增加和导尿需求对不满意度有影响。50例患者中,25例(50%)接受了重复BoNT-A注射;4例患者最终决定接受膀胱扩大肠囊成形术,因为他们希望得到永久性矫正且不愿接受重复注射。
患者满意度为78%,这些患者在接受逼尿肌BoNT-A注射治疗尿失禁和膀胱功能障碍后,生活质量得到改善。